Lihua Xu

Dr. Lihua Xu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2025 in Materials Today Bio
Verified
Journal Article
Open access
FZFan Zhang
Fan Zhang
LXLihua Xu
Lihua Xu
YWYafeng Wang
Yafeng Wang
PWPengju Wang
Pengju Wang
The anisotropic Au nanostars exhibit superior local electric field enhancement than their counterparts. Their longitudinal localized surface plasmon resonance (LSPR) wavelengths can be adjusted from visible to near infrared regions through morphological control. This review systematically synthesizes recent advances in star-shaped plasmonic nanoparticles, focusing on structure-property relationships and applications. A structured literature survey was conducted by screening peer-reviewed publications from databases period 2003–2025. The key insights include the defined classification frameworks of Au nanostars emphasizing three distinct nanostructures (fractal, hollow, and hybrid nanostructure), critical evaluation on the synthesis strategies and structural-property relationships of Au nanostars, applications in sensing and diagnostic, therapeutic application, and finally identification critical knowledge gaps and future research directions. These applications highlight the potential of Au nanostars in various biomedical and analytical fields. Despite significant progress, clinical translation remains challenging. The perspectives mainly include theoretical calculations, theoretical models, standardized preparation methods, and multi-stimuli responsive systems. We underscore the transformative potential of Au nanostars while highlighting the necessity for interdisciplinary collaboration to bridge existing gaps, provide some inspiration to develop novel functional nanomaterials with enhanced performance and ultimately accelerate their clinical translation.

5 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
YWYan WenYi
Yan WenYi
YXYujing Xuan
Yujing Xuan
RWRuimin Wang
Ruimin Wang
ZHZiyan Huan
Ziyan Huan
YGYu Guo
Yu Guo
PWPengju Wang
Pengju Wang
Objectives: Pancreatic cancer remains a therapeutic challenge due to its immunosuppressive microenvironment and treatment resistance. This study aimed to develop a novel recombinant oncolytic vaccinia virus (VVL-GL7) co-expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-7 (IL-7), designed to enhance anti-tumor immunity and synergize with immune checkpoint inhibitors. Methods: VVL-GL7 was constructed through CRISPR/Cas9-mediated knockout of TK and A49 genes, combined with the simultaneous insertion of dual cytokine-encoding cassettes. Anti-tumor efficacy was evaluated in vitro and in vivo using C57BL/6 mouse and Syrian hamster pancreatic cancer models. Comprehensive immune profiling evaluated CD8+ T-cell and macrophage infiltration dynamics while simultaneously assessing memory T-cell differentiation patterns using flow cytometry. Preclinical combination studies of VVL-GL7 and the PD-1 immune checkpoint inhibitor were systematically evaluated in a syngeneic pancreatic cancer model. Results: VVL-GL7 exhibited potent oncolytic activity, inducing significant tumor regression in both preclinical models. VVL-GL7 therapy significantly augmented CD8+ T-cell and macrophage infiltration within the tumor microenvironment, while concomitantly driving memory T-cell differentiation. The synergistic effects of VVL-GL7 and the PD-1 blockade further improved therapeutic outcomes, resulting in significantly higher tumor remission rates compared to monotherapy and achieving complete tumor regression in pancreatic cancer models. Conclusions: VVL-GL7 reprograms the immunosuppressive tumor microenvironment and synergizes with anti-PD-1 antibodies to overcome resistance in pancreatic cancer.


3 June 2026 in Materials Today Bio
Verified
Journal Article
Open access
YGYu Guo
Yu Guo
CHChunYao Huang
ChunYao Huang
LXLihua Xu
Lihua Xu
YXYujing Xuan
Yujing Xuan
PWPengju Wang
Pengju Wang
Oncolytic viruses (OVs) represent an emerging cancer therapeutic modality with dual functions of direct tumor cell lysis and activation of systemic antitumor immunity. However, the systemic delivery of OVs remains a significant challenge owing to immune barriers and the immunosuppressive tumor microenvironment (TME). Current delivery strategies can be broadly categorized into naked virus delivery and vector-based delivery. Each platform presents distinct advantages in enhancing delivery efficiency and antitumor immune activation, yet both share common challenges, including immune clearance and delivery stability. In this review, we provide a comprehensive summary of the advantages and limitations associated with these different delivery strategies. In summary, combining OVs with advanced delivery systems holds great promise for advancing personalized and precise cancer therapies. Future research should focus on the development of multifunctional platforms, the optimization of combination treatment regimens, and the establishment of regulatory frameworks to accelerate the clinical translation of OV-based therapies.